Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02041143
Other study ID # 13.19.MET
Secondary ID
Status Completed
Phase Phase 1
First received January 16, 2014
Last updated October 27, 2015
Start date February 2014
Est. completion date May 2014

Study information

Verified date October 2015
Source Nestlé
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Interventional

Clinical Trial Summary

This trial is an exploratory study in order to determine whether the ingestion of one type of protein (milk protein/CHO/Fat) vs.placebo (CHO/Fat) 2 hours before bed time results in the extension of the post-prandial window of anabolism during the night by increasing whole body protein balance as well as muscle protein fractional synthesis rate (FSR).


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date May 2014
Est. primary completion date May 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 55 Years to 65 Years
Eligibility Inclusion Criteria:

- Male

- Healthy as determined by the medical questionnaire and the medical visit including blood sampling

- 55-65y of age

- BMI (19.0 - 25.0 kg/ m²)

- Having signed the consent form

Exclusion Criteria:

- Digestive (intestinal, gastric, hepatic or pancreatic), renal or metabolic disease, as determined by the medical (screening) visit and a blood chemistry analysis (glucose, total cholesterol, LDL, HDL, triglycerides, aspartate transaminase, alanine aminotransferase, gamma glutamyl transpeptidase, C Reactive Protein, creatinin)

- Heart or other organ disease

- Arterial hypertension (Systolic pressure = 140 mmHg or diastolic pressure = 90 mmHg)

- Any clotting trouble (diagnosed by Prothrombin time (PT), activated Partial Thromboplastin Time (aPTT), fibrinogen measures and platelets number (the latter is part of a classical blood cells counting at screening)

- Any inflammatory disease in the past four weeks

- Use of specific medications

- Recent major surgery (3 months)

- History of major gastro-intestinal surgery (gastric bypass, intestinal resection etc…)

- History of cancer within the past year

- Significant weight loss during the last 3 months (5% and more)

- Food allergies, especially cow milk protein allergies

- Special diets especially vegetarian, high protein or weight loss program (anamnesis)

- Smokers

- High level structured exercise 3 times a week (e.g.: fitness club, competitions…)

- Have a high alcohol consumption (more than 2 drinks/day)

- Consumption of illicit drugs anamnesis only

- Having given blood within the last month, or willing to make a blood donation until one month following the end of the study

- Subject who cannot be expected to comply with the study procedures, including consuming the test products.

- Currently participating or having participated in another clinical trial during the last month prior to the beginning of this study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Milk protein
Study product will provide 25 g of protein to subjects.
Placebo
Product with no protein

Locations

Country Name City State
Switzerland Metabolic Unit Lausanne Vaud

Sponsors (1)

Lead Sponsor Collaborator
Nestlé

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary muscle FSR determination Muscle protein FSR (fractional synthesis rate) will be determined using primed constant infusions of [13C6] phenylalanine for 5 hours starting around from 03:00 a.m. (see flow chart attached). Whole body protein balance will be measured throughout the night using [15N]glycine (200mg) which will be orally taken with the trial product in the evening. Within 24 hours of product intake No
Secondary Activation of signaling pathways involved in skeletal muscle protein balance Activation of signaling pathways involved in skeletal muscle protein balance will be assessed through use of immunohistochemistry Within 24 hours after product intake No
Secondary Glucose metabolism Glucose metabolism will be assessed from circulating concentrations of glucose and insulin. Within 24 hours after product intake No
Secondary Plasma amino acid availability The quantification of Free Amino Acids in Human Plasma will be done by Amino Acid Analyser Biochrome 30. Within 24 hours after product intake No